hotspot -WSS

hotspot

author：explore 2025-08-27 22:46:15 - browse：5

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

entertainment

leisure time

WSS

Hospitals use virtual reality to design more inclusive rooms for kids

Study: Pain burden is higher in Black NFL players than white ones

It's time to get medical device identifiers over the finish line

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

It's time to get medical device identifiers over the finish line

Sage's campaign to raise awareness of postpartum depression hits a nerve

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

23andMe had bad news about my health. I wish a person had delivered it

Beach reads and more: STAT's 2023 summer book list

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

United colonoscopy coverage change 'may cost lives,' doctors say

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Anesthesiologist group: stop taking Ozempic before surgery

It's time to get medical device identifiers over the finish line

Malaria cases in Florida and Texas: Here’s what you need to know

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

hotspot

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

California’s proposed $25 per hour health care minimum wage

In venture capital firm's success, lessons for turning crisis into profit

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Judge rejects Trump's counterclaim against E. Jean Carroll

Retired US general questions alleged Putin, Prigozhin meeting

explore

entertainment

leisure time

leisure time